Benzinga | Sep 24, 2021 05:20AM EDT

Stifel Initiates Coverage On Editas Medicine with Hold Rating, Announces Price Target of $65

Stifel analyst Dae Gon Ha initiates coverage on Editas Medicine (NASDAQ:EDIT) with a Hold rating and announces Price Target of $65.